Article

FDA OKs ADHD Medication

The FDA has approved an extended-release amphetamine (Adzenys ER, Neos Therapeutics) oral suspension for treating attention-deficit hyperactivity disorder (ADHD), according to a company press release.1 Once commercially available, Adzenys ER oral suspension will be the third Neos extended release product for the treatment of ADHD, joining Adzenys XR-ODT® (amphetamine) Extended-Release Orally Disintegrating Tablets and Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets.

Adzenys ER, formerly referred to as NT-0201, is a once-daily, extended-release liquid medication that does not require refrigeration or reconstitution at the pharmacy level, according to the release.

“It is important for physicians to have a wide choice of medicines to help our patients with ADHD manage their symptoms,” Michael Feld, MD, a Northbrook, IL-based Child, Adolescent, and Adult Psychiatrist specializing in the treatment of ADHD said in a press release. “As a once-daily liquid formulation, Adzenys ER can play a role in meeting the individual needs of my patients.”

Adzenys ER is expected to become available in early 2018.

Reference

Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older (news release). Dallas, TX. http://investors.neostx.com/phoenix.zhtml?c=254075&p=RssLanding&cat=news&id=2301045. Accessed September 15, 2017.

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com